Natural product-derived therapy for glucose homeostasis and TIIDM: Berberine, isolated from Berberis, Hydrastis Canadesis, and Berberis aristata, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4, 14/February/2017, 11.41 pm

Steroid-based Cancer immunotherapy: 17β-Estradiol (E2) inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 14/February/2017, 7.02 pm
February 14, 2017
Anti-telomerase cancer therapy: Guttiferone, isolated from Garcinia Cambogia, suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and the cellular immortality gene telomerase and inhibits cancer progression via down-regulation of it target gene, 15/February/2017, 6.45 am
February 15, 2017
Show all

Introduction: What they say

Nobel laureate in Physiology/Medicine (1975) Prof. David Baltimore and his research team, from California Institute of Technology, California, USA, had reported in the September 14, 2014 issue of the Journal “Journal of Experimental Medicine (JEM)” that: “The microRNA-212/132 cluster regulates B cell development by targeting Sox4.”

Subsequently, Prof. Rorsman’s research team, from Oxford Centre for Diabetes, Endocrinology & Metabolism, Radcliffe Department of Medicine, Oxford, U.K; Department of Neuroscience and Physiology, University of Göteborg, Göteborg, Sweden Oxford; and National Institute of Health Research, Biomedical Research Centre, Churchill Hospital, Oxford, U.K, had reported in the March 18, 2016 issue of the Journal “Diabetes” that Increased Expression of the Diabetes Gene SOX4 Reduces Insulin Secretion by Impaired Fusion Pore Expansion.”


What we say:

On the foundation of these interesting findings, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for glucose homeostasis and TIIDM: Berberine, isolated from Berberis, Hydrastis Canadesis, and Berberis aristata, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4.


From Significance of the study to Public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


From what is known to what we infer from what they say:

Prof. Rorsman’s research team has recently shown that overexpression of Sox4 results in: (1) increased expression of Amysin; (2) reduction in fusion pore size; (3) impairment of granule emptying; (4) impairment of insulin exit; (5) prevention of hormone release; and (6) reduction of glucose-induced insulin secretion, suggesting that decreasing the expression of Sox4 and its target gene Amysin in diabetic patients may alleviate TIIDM.


From Research findings to Therapeutic opportunity:

Berberine inhibits Sox4 and its target gene amysin via up regulaiton of mir132.212

Figure 1. Mechanistic insight into how Berberine promotes insulin sensitivity. Berberine, found in Berberis, decreases Sox4 and its target gene Amysin and promotes insulin secretion

Berberine, by increasing the expression of its target genes, it may decrease the expression of Sox4 (fig.1).price-300

Thereby, it may: (1) decrease the expression of exocytosis-regulating protein Amysin; (2) promote granule emptying and insulin release; and (3) increase glucose-induced-insulin secretion (Fig.1). Thus, pharmacological formulations encompassing “Berberine or its analogues either alone or in combination with other drugs” may be used to treat TIIDM.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Berberine decrease the expression of SOX4 and its target gene Amysin to increase insulin secretion?

Amount: $300

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Natural product-derived therapy for glucose homeostasis and TIIDM: Berberine, isolated from Berberis, Hydrastis Canadesis, and Berberis aristata, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4, 14/February/2017, 11.41 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.